APOLLO BEACH, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today a new laboratory lease agreement with life science incubator MBC BioLabs for a brand new facility located in San Carlos, California. The lease includes an option for Mission BioCapital, an affiliate of MBC Biolabs, to potentially invest in RetinalGenix. The Company plans to use... Read More

APOLLO BEACH, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), today announced it will participate at the 37 th Annual Roth Conference on March 16 th to 18 th . The Company will highlight its proprietary high-resolution, real-time retinal and ocular imaging and monitoring RetinalCam™, which is currently imaging patients and is in the prototype stage.... Read More

APOLLO BEACH, Fla., Feb. 20, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today that it has achieved an important milestone in developing its high-resolution retinal imaging device and remote monitoring system. The Company has successfully started imaging patients with its first prototype of its device using both near-infrared and green modes. The images... Read More

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy. The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes.... Read More

PETALUMA, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”), today announced that it has contracted with MEDsan, Inc. (“MEDsan” to provide diagnostic testing services for its Institutional Review Board (IRB) to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration , which was previously... Read More

PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™... Read More

PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors. RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™... Read More

PETALUMA, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”) today announced that it has hired Virender Ahluwalia as Interim Chief Financial Officer. The Company is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies. Mr.... Read More

PETALUMA, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Stephen Tannenbaum to the Business Advisory Board of RetinalGeniX. Mr. Tannenbaum will provide strategic business advice, consult on potential mergers and acquisitions, and the development of channels to acquire additional capital for the Company. "We are excited... Read More

PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024. RTG-2023 is being developed to treat dry age-related macular degeneration (AMD). There are two forms of the disease; wet... Read More

PETALUMA, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with Avania CRO to provide guidance for the Company’s interactions with the FDA for the development of [1] RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD) and [2] RTG-2024 for the treatment of Alzheimer’s syndrome dementia, and... Read More

PETALUMA, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced the launch of an Institutional Review Board (“IRB”) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the preselection process and management of ocular injections. The proposed patient selection process has the potential to reduce the cost... Read More

PETALUMA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) released to the public via OTC Markets , a video webinar regarding the retinal screening medical device technology being developed by the Company to help prevent blindness and multiple systemic diseases, the Company’s business opportunities and the professional background of the Company’s... Read More

PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™. He will also advise RTGN on its other corporate activities. In this capacity, specifically, he will (a) participate in therapeutic drug selection and development and (b) assist in linking... Read More

PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring and Integrated Physician Alert System For Ocular Anatomy. The invention relates to a home monitoring device deployed in the patient's home, from which an alert can be sent to a remotely located physician, who can then perform a... Read More

PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board (“IRB”) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the management of ocular injections, which have become a significant healthcare burden due to their associated complications in... Read More

PETALUMA, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the hiring of Owen Watson, MS. Mr. Watson’s efforts will be devoted to helping to accelerate the commercialization of the company’s software application, " DNA/GPS ." The application is expected to allow patients to obtain their genetic systemic bio-markers privately,... Read More